Literature DB >> 15029111

Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure.

Peter A McCullough1, Joseph Kuncheria, Vandana S Mathur.   

Abstract

Chronic kidney disease (CKD) and congestive heart failure (CHF) are epidemiologically and pathophysiologically linked. A recent study in patients with severe CHF demonstrated that renal plasma flow was inversely correlated with pulmonary capillary wedge pressure, right atrial pressure, pulmonary pressure, and right ventricular ejection fraction. This article reviews the utility of B-type natriuretic peptide (BNP) levels in assessing cardiac function and volume status in patients with CKD and examines the safety and efficacy of BNP therapy in patients with renal insufficiency and decompensated heart failure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15029111

Source DB:  PubMed          Journal:  Rev Cardiovasc Med        ISSN: 1530-6550            Impact factor:   2.930


  3 in total

Review 1.  Assessing cardiovascular risk in children with chronic kidney disease. B-type natriuretic peptide: a potential new marker.

Authors:  Gema Ariceta; Ellen R Brooks; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2005-08-05       Impact factor: 3.714

2.  Brain natriuretic peptide as a potential novel marker of salt-sensitivity in chronic kidney disease patients without cardiac dysfunction.

Authors:  Mutsuharu Hayashi; Yoshinari Yasuda; Susumu Suzuki; Manaka Tagaya; Takehiro Ito; Tomohito Kamada; Masataka Yoshinaga; Yoshinori Sugishita; Wakaya Fujiwara; Hiroatsu Yokoi; Yukio Ozaki; Hideo Izawa
Journal:  Heart Vessels       Date:  2016-07-06       Impact factor: 2.037

3.  Cardiorenal syndrome in thalassemia patients.

Authors:  Sorasak Makmettakul; Adisak Tantiworawit; Arintaya Phrommintikul; Pokpong Piriyakhuntorn; Thanawat Rattanathammethee; Sasinee Hantrakool; Chatree Chai-Adisaksopha; Ekarat Rattarittamrong; Lalita Norasetthada; Kanda Fanhchaksai; Pimlak Charoenkwan; Suree Lekawanvijit
Journal:  BMC Nephrol       Date:  2020-08-03       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.